NO20064985L - Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer - Google Patents

Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer

Info

Publication number
NO20064985L
NO20064985L NO20064985A NO20064985A NO20064985L NO 20064985 L NO20064985 L NO 20064985L NO 20064985 A NO20064985 A NO 20064985A NO 20064985 A NO20064985 A NO 20064985A NO 20064985 L NO20064985 L NO 20064985L
Authority
NO
Norway
Prior art keywords
treatment
diagnostics
activated receptor
peroxisome proliferator
demyelinating diseases
Prior art date
Application number
NO20064985A
Other languages
English (en)
Norwegian (no)
Inventor
Anne Minnich
Jean Merrill
Olga Khorkova
Karen Chandross
Lan Lee
Yun Liu
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20064985L publication Critical patent/NO20064985L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20064985A 2004-04-01 2006-10-31 Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer NO20064985L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (1)

Publication Number Publication Date
NO20064985L true NO20064985L (no) 2006-10-31

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064985A NO20064985L (no) 2004-04-01 2006-10-31 Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer

Country Status (16)

Country Link
US (1) US20070149580A1 (xx)
EP (1) EP1737440A2 (xx)
JP (1) JP2007530703A (xx)
KR (1) KR20060134191A (xx)
CN (1) CN1950077A (xx)
AU (1) AU2005231358A1 (xx)
BR (1) BRPI0509540A (xx)
CA (1) CA2561159A1 (xx)
IL (1) IL178165A0 (xx)
MA (1) MA28561B1 (xx)
MX (1) MXPA06011218A (xx)
NO (1) NO20064985L (xx)
RU (1) RU2006138495A (xx)
SG (1) SG138623A1 (xx)
WO (1) WO2005097098A2 (xx)
ZA (1) ZA200607850B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
WO2007061094A1 (ja) * 2005-11-28 2007-05-31 Senju Pharmaceutical Co., Ltd. Ｐｐａｒアゴニスト含有医薬
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
EP2288607B1 (en) 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
RU2010154279A (ru) 2008-06-09 2012-07-20 Санофи-Авентис (Fr) Аннелированные n-гетероциклические сульфонамиды с оксадиазолоновой концевой группой, способы их получения и их применение в качестве фармацевтических препаратов
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
RU2016138560A (ru) 2009-12-17 2018-12-13 Санофи Животная модель, экспрессирующая люциферазу под контролем промотора основного белка миелина (mbp-luci), и применение модели для визуализации биолюминесценции in vivo
ES2716865T3 (es) * 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
US20070149580A1 (en) 2007-06-28
SG138623A1 (en) 2008-01-28
RU2006138495A (ru) 2008-05-10
KR20060134191A (ko) 2006-12-27
WO2005097098A2 (en) 2005-10-20
CA2561159A1 (en) 2005-10-20
ZA200607850B (en) 2008-10-29
JP2007530703A (ja) 2007-11-01
MXPA06011218A (es) 2007-01-16
AU2005231358A1 (en) 2005-10-20
EP1737440A2 (en) 2007-01-03
WO2005097098A3 (en) 2005-12-22
CN1950077A (zh) 2007-04-18
MA28561B1 (fr) 2007-04-03
BRPI0509540A (pt) 2007-09-18
IL178165A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20064985L (no) Anvendelse av peroksisom proliferatoraktiverte reseptor deltaagnoister for behandling av MS og andre demyelinerende sykdommer
US20230201032A1 (en) Method and device for treating an ocular disorder
Hatzifotis et al. Hydrofluoric acid burns
Moore et al. Rehabilitation of the burned hand
US20140214062A1 (en) Method and device for treating an ocular disorder
US20140276281A1 (en) Method and device for treatment of joint pain
Can Dupuytren’s contracture
Xu et al. Rehabilitation effects of fatigue-controlled treadmill training after stroke: a rat model study
Bigorre et al. Lateral epicondylitis treatment by extensor carpi radialis fasciotomy and radial nerve decompression: is outcome influenced by the occupational disease compensation aspect?
SM et al. Effectiveness of conservative management of acute fissure in ano: a prospective clinical study of 165 patients
Taheri et al. Radial extracorporeal shock wave therapy for Dupuytren’scontracture: a case report
Sweilam et al. Extracorporeal shock wave therapy (ESWT) versus local steroids injection in the management of carpal tunnel syndrome
RU2262962C2 (ru) Способ лечения компрессионно-ишемических невропатий
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
Zhang et al. Study on the effect, safety, prognosis quality and application value of extracorporeal shock wave based neural activity in carpal tunnel syndrome patients
Zeinali et al. Comparison of the effects of kinesio taping to local injection of methyl prednisolone in treating brachial biceps tendonitis
CN107213224A (zh) 一种舒筋活血酒
Diwadkar et al. Immediate effectiveness of positional release therapy in acute ankle sprain
Zayed Cryotherapy for managing oral biofilms: beyond biofilm removal
Laffont 2019 Sidney Licht Lecture: Spasticity and related neuro-orthopedic deformities: A core topic in physical and rehabilitation medicine
Ramana et al. Efficacy of Therapeutic Ultrasound and Therapeutic Laser Along with Myofascial Release in Reducing Pain and Improving Hand Grip for People with Lateral Epicondylitis.
RU2366398C1 (ru) Способ устранения болевого синдрома в ягодичной области
Wang Therapeutic Effect of Chinese Massage Combined with Warm Acupuncture on Knee Osteoarthritis
Poonsuk et al. Comparing Treatment Efficacy of Court-type Traditional Thai Massage, Elastic Taping, and Stretching for Plantar Fasciitis: A Three-Armed Randomized Controlled Trial
Shivachev et al. Oncology Rehabilitation-an alternative to breast cancer treatment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application